INNOVATE Corp. reported its third quarter 2026 financial results, highlighted by a 42.8% increase in revenue to $495.5 million and a return to profitability with net income of $15.8 million. During the period, the company executed major strategic divestitures, including the sale of a controlling interest in HC2 Broadcasting and the completion of the DBM Global sale to IES Holdings shortly after quarter-end.
Term
Q3 2026
“DBM Global capped its final quarter under our ownership with exceptional performance, and we took two significant steps to reshape our portfolio through the sale of a controlling interest in HC2 Broadcasting and, shortly after quarter-end, the sale of DBM Global to IES. These transactions mark meaningful progress in our efforts to unlock the value of our assets, generate funds to help address coming debt repayment and redemption obligations, and further simplify INNOVATE's portfolio and capital structure.”
Avie Glazer, Chairman of INNOVATE
“Our focus now turns to the opportunities within our remaining portfolio, addressing liquidity and continuing to maximize value for INNOVATE shareholders. MediBeacon continues to build commercial momentum and advance its commercialization efforts in the U.S. and China, while HC2 Broadcasting is actively pursuing initiatives to unlock greater potential for its spectrum assets.”
Sanara MedTech reported net revenue of $84.4 million for the nine months ended September 30, 2026, a 12% increase over the prior year. Despite higher gross profits, the company recorded a net loss of $1.4 million for the period, primarily due to increased selling, general, and administrative expenses and interest costs.
Lulu’s Fashion Lounge reported a 20% decline in Q3 2026 net revenue to $58.6 million, driven by lower order volumes and higher return rates. Despite the revenue headwind, the company achieved a 230-basis-point gross margin expansion and a 17% reduction in inventory as it continues an assortment reset strategy.
Term
Q3 2026
“During the third quarter, we continued to advance our assortment reset and saw encouraging signs from newer product, even as the impact of historical assortment decisions remained a headwind to customer engagement and repeat purchasing behavior. While these pressures continue to weigh on revenue, we are encouraged by the improving productivity and reorder eligibility of 2026 product introductions, which reinforces our confidence that refocusing the assortment on the categories and customers where Lulus has historically differentiated itself is the right path to rebuilding customer engagement over time.”
Crystal Landsem, CEO of Lulus
“Throughout the third quarter, we maintained a disciplined approach to inventory management, expense control and working capital as we continued to drive greater efficiency across the business.”
Codexis reported Q3 2026 revenue of $19.3 million, a significant increase from $8.6 million in the prior year, driven by higher product revenue from new customer launches. The company also highlighted a new $60 million term loan facility with Trinity Capital and the successful scale-up of its ECO Synthesis Manufacturing Platform to 100-gram scale.
Term
Q3 2026
“I am pleased with our outstanding progress in 2026, through both innovation and technical achievements, that has garnered attention from leading innovators in the siRNA field.”
Alison Moore, PhD, President and Chief Executive Officer
“We have made significant progress in industrializing our technology while simultaneously increasing our revenue base, managing expenses, and improving the financial stability of our company.”
Alison Moore, PhD, President and Chief Executive Officer
Decoy Therapeutics Inc. reported a net loss of $7.59 million for the nine months ended September 30, 2026, compared to a $3.54 million loss in the prior year period, driven by a significant increase in research and development expenses. The company recognized $535,059 in grant revenue during the period and maintains a cash balance of approximately $8.17 million as of September 30, 2026.
ImmuCell Corporation reported a settlement of $2.0 million with a former contract manufacturer and a $0.1 million regulatory fee reversal following the decision to cease focus on Re-Tain®. The company is currently refitting approximately $11.8 million in idle manufacturing assets for First Defense® production and reported anti-dilutive stock options totaling 968,978 for the quarter ended September 30, 2026.
VolitionRx reported total revenues of $3.0 million for the nine months ended September 30, 2026, a significant increase from $1.3 million in the prior year, primarily driven by product sales. Despite higher revenues, the company recorded a net loss of $17.8 million for the period, impacted by $15.9 million in operating expenses and $5.0 million in other expenses including debt extinguishment costs.
SoundThinking reported a net loss of $20.2 million for the first nine months of 2026, a significant increase from the $6.6 million loss in the prior year period, driven by a decline in revenues and higher general and administrative expenses. The company also announced a pending acquisition by Transom Capital Group, LLC, which has introduced uncertainties regarding the transaction's completion and its impact on business operations.
For the nine months ended September 30, 2026, Lineage Cell Therapeutics reported total revenues of $4.2 million, a decrease from $7.9 million in the prior year, primarily due to lower collaboration revenues. The company significantly reduced its net loss compared to 2025, aided by a substantial $31.2 million non-cash gain from the change in fair value of warrant liabilities.
For the nine months ended September 30, 2026, Park Dental Partners reported revenue of $193.8 million, a 5.8% increase year-over-year, though net income decreased to $2.7 million from $5.4 million due to higher salaries and share-based compensation. The company maintained a solid liquidity position with $23.2 million in cash and cash equivalents while continuing to expand through dental practice acquisitions.
For the nine months ended September 30, 2026, Antares Strategic Credit Fund reported total investment income of $297.1 million and net investment income of $143.4 million. The fund's net asset value per share decreased to $25.02 from $25.42 at the end of 2025, primarily driven by $30.9 million in net realized and unrealized losses.
York Space Systems reported Q3 2026 revenue of $84.2 million and a significant net loss of $807.4 million, primarily driven by a $749.7 million non-cash goodwill impairment charge. The company highlighted a 30% expansion in its identified pipeline and the appointment of Brian Frantz as permanent CFO.
Term
Q3 2026
“Our identified pipeline grew more than 30 percent compared to last quarter, and we have secured the critical contract positions needed to compete for significant awards in 2027 and beyond, with IDIQ awards already converting into funded task orders.”
Dirk Wallinger, CEO of York
“Our contribution margins continue to benefit from the shift to newer programs, and we see a long-term trend toward increased profitability as we move up the value chain.”
Cardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, compared to $38.6 million in the prior year period. The company strengthened its balance sheet through the issuance of common stock and warrants, raising approximately $9.1 million in net proceeds during the third quarter of 2026.
For the nine months ended September 30, 2026, Everest Reinsurance Holdings reported net income of $797 million, an increase from $541 million in the prior year period, despite a decrease in earned premiums. The company's total stockholder's equity remained stable at $8.5 billion, as net income was largely offset by $793 million in other comprehensive losses primarily driven by unrealized depreciation of securities.
Scribe Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $174.2 million following its successful upsized IPO. The company is advancing its Phase 1 clinical trial for STX-1150, an epigenetic silencing therapy for LDL-C lowering, with initial data expected in the first half of 2027.
“This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients.”
Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics
ProMIS Neurosciences reported a significant increase in cash to $44.1 million as of September 30, 2026, compared to $6.1 million at the end of 2025, primarily driven by financing activities that increased additional paid-in capital. The company's accumulated deficit grew to $158.5 million, reflecting ongoing research and development costs, while total shareholders' equity improved to a positive $41.8 million.
Crown Crafts reported second quarter fiscal 2027 results, with net income increasing to $1.3 million despite a decline in net sales to $19.0 million. The company achieved a significant gross margin expansion to 32.0%, driven by profitability initiatives and tariff refunds, and declared a quarterly dividend of $0.03 per share.
Term
Q2 2027
“We continue to execute well on our profitability initiatives with meaningful improvement this quarter in our gross profit, marketing and administrative expenses, and year-to-date operating cash flow.”
Olivia Elliott, President and Chief Executive Officer
“Our stronger profitability reflects our continued initiatives around efficiency and profitability, and our talented team is simultaneously focused on the development of additional higher-margin products and sales channels to grow both sales and profitability in the quarters ahead.”
Olivia Elliott, President and Chief Executive Officer
4D Molecular Therapeutics is a clinical-stage genetic medicine company reporting 56,379,402 shares of common stock outstanding as of November 9, 2026. The company continues to incur significant net losses and requires substantial additional capital to fund the development of its lead AAV product candidates, including 4D-150 and 4D-175.
AEVEX Corp. filed its 10-Q for the period ending September 30, 2026, highlighting the recent acquisition of Maritime Applied Physics Corporation (BlackSea) and its ongoing integration. The company continues to operate as a non-accelerated filer and emerging growth company following its April 2026 initial public offering.
GCT Semiconductor reported total net revenues of $3.96 million for the nine months ended September 30, 2026, an increase from $2.11 million in the prior year period. Despite the revenue growth, the company incurred a net loss of $37.63 million for the period, driven by high operating expenses and a significant $9.23 million loss from the change in fair value of common stock warrant liabilities.
Electra Therapeutics is a clinical-stage biotechnology company focused on SIRP-targeted therapies, specifically its lead candidates ipsoprubart and ELA822. As of November 2026, the company remains pre-revenue with significant operating losses and expects to require substantial additional capital to fund its research and development programs.
Atrium Therapeutics reported a net loss of $41.1 million for the nine months ended September 30, 2026, compared to $20.4 million in the prior year period, driven by a significant increase in general and administrative expenses following its spin-off. The company ended the quarter with $232.1 million in cash, cash equivalents, and short-term investments, bolstered by a $313.4 million transfer from its former parent company.
U.S. Global Investors reported its first quarter fiscal 2027 results, achieving 18% revenue growth to $2.7 million and returning to operating profitability. The company saw a 14% year-over-year increase in average assets under management to $1.6 billion, driven largely by a 45% surge in gold and precious metals strategies.
Term
Q1 2027
“Gold miners continued to draw investor interest during the quarter, and that showed up in our asset levels. Average assets in our gold strategies are up more than 45% from a year ago. We believe disciplined, actively managed exposure to high-quality miners remains an important part of a diversified portfolio, and we’re pleased that more investors appear to agree.”
Frank Holmes, CEO and Chief Investment Officer
“Defense is no longer defined just by aircraft and ships. It’s increasingly being reshaped by artificial intelligence (AI), autonomous systems and cybersecurity. As governments around the world direct more spending toward national security, we believe WAR, our actively managed Smart Beta 2.0 ETF, gives investors targeted exposure to the companies driving that transformation.”
MultiSensor AI Holdings reported a net loss of $1.95 million for the quarter ended September 30, 2026, a slight increase from the $1.68 million loss in the prior year period. While nine-month revenue grew to $4.81 million from $4.16 million, the company continues to experience operating losses and negative cash flow from operations as it expands its SaaS capabilities and condition intelligence platform.
ProMIS Neurosciences reported Q3 2026 financial results, ending the period with $44.1 million in cash which is expected to fund operations through 2027. The company reaffirmed that topline data from its Phase 1b PRECISE-AD trial of PMN310 in Alzheimer’s disease remains on track for the first quarter of 2027.
Term
Q3 2026
“The third quarter of 2026 has been productive for ProMIS, following encouraging interim data from our Phase 1b PRECISE-AD trial in Alzheimer’s disease (AD). Based on data generated to date, we continue to believe PMN310 offers a differentiated approach by selectively targeting the most toxic and destructive form of amyloid-beta, the oligomers.”
Neil Warma, President and Chief Executive Officer
“With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures.”
Alumis Inc. reported total assets of $488.7 million as of September 30, 2026, supported by a significant increase in marketable securities following its IPO. The company is focused on the development of envudeucitinib (envu) for plaque psoriasis, with plans to submit a New Drug Application by the end of 2026.
Park Dental Partners reported third quarter 2026 revenue of $64.9 million, a 6% increase year-over-year driven by reimbursement trends and acquisitions. Net income rose 36.1% to $1.7 million, although diluted EPS decreased to $0.27 compared to $0.72 in the prior-year period. The company also highlighted the completion of the Village Family transaction, expanding its network into a fourth state.
Term
Q3 2026
“Third-quarter revenue increased 6%, supported by same-practice growth, an expanding affiliated doctor base and contributions from recently acquired practices. We have made meaningful progress adding clinical capacity and strengthening our platform, and our focus now is converting that capacity and revenue growth into improved productivity and stronger earnings performance.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
“The completion of the Village Family transaction represents an important step in our growth strategy and extends our affiliated practice network into a fourth state. We remain focused on disciplined integration, supporting our affiliated practices and executing against the opportunities already within our business.”
Pete Swenson, Chief Executive Officer and Chair of the Board of Directors
Carlyle Private Equity Partners Fund, L.P. reported total assets of $477.3 million as of September 30, 2026, a significant increase from $59.0 million at the end of 2025. The fund's investment portfolio grew to a fair value of $280.4 million, supported by substantial cash and cash equivalents of $194.2 million.
ProKidney Corp. reported third quarter 2026 financial results, ending the period with $141.9 million in cash and marketable securities to fund operations into mid-2027. The company remains on track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint topline results in Q2 2027. R&D expenses increased to $40.8 million, driven by clinical study and manufacturing costs for the ongoing rilparencel program.
Term
Q3 2026
“The third quarter marked continued progress for ProKidney, with PROACT 1 advancing toward full enrollment and our pivotal eGFR slope topline readout remaining on track for the second quarter of 2027. The data presented at Kidney Week further build the mechanistic and clinical evidence supporting rilparencel and provide a more cohesive picture of how it may stabilize kidney function. Together, these advances reinforce our confidence as we approach this important Phase 3 readout and continue our mission to transform the treatment of advanced CKD.”
Dragonfly Energy reported Q3 2026 net sales of $12.2 million, down 23.8% year-over-year due to softness in the RV market, though heavy-duty trucking revenue more than doubled sequentially. The company completed the acquisition of the Dakota Lithium brand during the quarter and expects to reach approximately breakeven Adjusted EBITDA in Q4 2026.
Term
Q3 2026
“Third quarter heavy-duty trucking revenue more than doubled sequentially to $1.3 million, in line with our August outlook, driven by expanding commercial fleet adoption. For the first time, we received orders from fleets moving directly into commercial deployment without a pilot program, reflecting the credibility we have established through years of field validation.”